These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35598595)

  • 1. Early Physiological and Adrenal Effects of Budesonide Mixed with Surfactant in Large Observational Preterm Cohort Study.
    Becker SA; Kothe TB; Josephsen JB; Jackson K; Williams HL; Hillman NH
    Neonatology; 2022; 119(4):474-482. PubMed ID: 35598595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial.
    Marzban A; Mokhtari S; Tavakkolian P; Mansouri R; Jafari N; Maleki A
    BMC Pediatr; 2024 Apr; 24(1):262. PubMed ID: 38643076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.
    Manley BJ; Kamlin COF; Donath S; Huang L; Birch P; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Wilson R; Davis PG; McKinlay CJD
    Trials; 2023 May; 24(1):320. PubMed ID: 37161488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactant and budesonide for respiratory distress syndrome: an observational study.
    Kothe TB; Sadiq FH; Burleyson N; Williams HL; Anderson C; Hillman NH
    Pediatr Res; 2020 Apr; 87(5):940-945. PubMed ID: 31715622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants.
    Moschino L; Nardo D; Bonadies L; Stocchero M; Res G; Priante E; Salvadori S; Baraldi E
    Pediatr Pulmonol; 2021 Jul; 56(7):2114-2124. PubMed ID: 33942570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial.
    Liu MM; Ji L; Dong MY; Zhu XF; Wang HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jan; 24(1):78-84. PubMed ID: 35177180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.
    Yeh TF; Chen CM; Wu SY; Husan Z; Li TC; Hsieh WS; Tsai CH; Lin HC
    Am J Respir Crit Care Med; 2016 Jan; 193(1):86-95. PubMed ID: 26351971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia.
    Heo M; Jeon GW
    Turk J Pediatr; 2020; 62(4):551-559. PubMed ID: 32779407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis.
    Venkataraman R; Kamaluddeen M; Hasan SU; Robertson HL; Lodha A
    Pediatr Pulmonol; 2017 Jul; 52(7):968-975. PubMed ID: 28165675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial.
    Francis KL; McKinlay CJD; Kamlin COF; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Davis PG; Donath SM; Manley BJ
    Trials; 2023 Nov; 24(1):709. PubMed ID: 37932774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratracheal Instillation of Budesonide-Surfactant for Prevention of Bronchopulmonary Dysplasia in Extremely Premature Infants.
    Dolma K; Zayek M; Gurung A; Eyal F
    Am J Perinatol; 2024 May; 41(S 01):e3065-e3073. PubMed ID: 37913780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presumed adrenal insufficiency in neonates treated with corticosteroids for the prevention of bronchopulmonary dysplasia.
    Josephsen JB; Hemmann BM; Anderson CD; Hemmann BM; Buchanan PM; Williams HL; Lubsch LM; Hillman NH
    J Perinatol; 2022 Jan; 42(1):65-71. PubMed ID: 34725449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
    Stevens TP; Harrington EW; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003063. PubMed ID: 17943779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of minimally invasive pulmonary surfactant administration in preterm infants with neonatal respiratory distress syndrome: a multicenter clinical trial].
    Liu HQ; Tong XM; Han TY; Zhang H; Guo M; Zhang XF; Liu XJ; Zhang X; Zhang MT; Liu F; Bao LS; Zheng J; Tian XY; Gao Q; Zhang WX; Duan Y; Sun FF; Guo W; Li L; Xiao M; Liu WL; Jiang R
    Zhonghua Er Ke Za Zhi; 2020 May; 58(5):374-380. PubMed ID: 32392952
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants.
    Kaniewska U; Gulczyńska E
    Dev Period Med; 2019; 23(3):163-171. PubMed ID: 31654994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy analysis of different pulmonary surfactants in premature infants with respiratory distress syndrome].
    Xu H; Xu P
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):174-179. PubMed ID: 33729136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants.
    Shah SS; Ohlsson A; Halliday HL; Shah VS
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD002057. PubMed ID: 29035425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis.
    Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y
    Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE).
    McEvoy CT; Ballard PL; Ward RM; Rower JE; Wadhawan R; Hudak ML; Weitkamp JH; Harris J; Asselin J; Chapin C; Ballard RA
    Pediatr Res; 2020 Oct; 88(4):629-636. PubMed ID: 32006953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.